Table 2

Forearm blood flow

Control subjects (n = 16)

Migraine patients (n = 16)


Sodium nitroprusside dose, μg.min-1.dL-1 forearm

0

0.2

0.4

0.8

0

0.2

0.4

0.8

non-infused arm

2.0 ± 0.9

1.9 ± 0.7

1.8 ± 0.8

1.8 ± 0.8

2.0 ± 0.5

2.0 ± 0.6

2.1 ± 0.8

1.9 ± 0.6

infused arm

2.0 ± 0.5

8.6 ± 3.5

10.9 ± 4.2

14.5 ± 5.9*

2.1 ± 0.5

8.7 ± 2.9

12.1 ± 4.6

16.5 ± 6.2*

Substance P dose, pmol.min-1.dL-1 forearm

0

0.2

0.4

0.8

0

0.2

0.4

0.8

non-infused arm

1.8 ± 0.8

1.8 ± 0.7

1.8 ± 0.7

1.9 ± 0.8

2.0 ± 0.6

1.9 ± 0.6

2.1 ± 0.6

2.0 ± 0.6

infused arm

2.2 ± 0.7

5.5 ± 2.2

6.9 ± 2.5

8.7 ± 3.8*

2.5 ± 0.7

5.1 ± 1.2

6.5 ± 1.8

8.4 ± 2.5*

L-NMMA dose, μmol.min-1.dL-1 forearm

0

0.1

0.2

0.4

0

0.1

0.2

0.4

non-infused arm

1.7 ± 0.5

1.8 ± 0.7

1.9 ± 0.9

1.9 ± 0.8

2.1 ± 0.5

1.9 ± 0.6

2.1 ± 0.6

2.4 ± 0.8

infused arm

2.0 ± 0.5

1.7 ± 0.4

1.6 ± 0.4

1.4 ± 0.4*

2.5 ± 0.6

2.0 ± 0.5

1.9 ± 0.6

1.9 ± 0.6*


Data are expressed as absolute blood flows (ml.min-1.dL-1 forearm); *P < 0.001 (ANOVA)

Vanmolkot and de Hoon BMC Neurology 2010 10:119   doi:10.1186/1471-2377-10-119

Open Data